Introduction
============

Papillary thyroid cancer (PTC) is the most common histological subtype of thyroid carcinoma, accounting for \> 80% of all thyroid malignancies \[[@b1-crt-2016-325]-[@b4-crt-2016-325]\]. Improvements in diagnostic modalities (including ultrasonography) have led to a recent and rapid increase in the detection of PTC, especially nonsymptomatic, node-negative, early-stage PTC \[[@b5-crt-2016-325]-[@b8-crt-2016-325]\]. As defined by the current American Joint Committee on Cancer (AJCC) TNM staging system, T1 PTCs have a diameter of ≤ 2 cm \[[@b9-crt-2016-325]\]. They are further subclassified as T1a (≤ 1 cm) or T1b (\> 1 cm but ≤ 2 cm), which can influence a patient's treatment plan. Moreover, the 2015 revision of the American Thyroid Association guidelines permits active surveillance instead of immediate surgery in select patients with an intrathyroid tumor diameter of ≤ 1 cm \[[@b10-crt-2016-325]\].

Although tumor diameter is widely used as the standard for treatment planning, it may not precisely reflect the true tumor burden because tumors do not always have a spherical shape. For example, tumors that are relatively long and narrow would have a lesser tumor volume and burden than those with a diameter equal to that of cylindrical tumors. Ultrasonography has shown that PTCs are typically long and narrow. Therefore, we investigated whether tumor volume would more accurately reflect tumor burden, resulting in more accurate prognosis, compared with tumor diameter. To accomplish this, prognostic values of preoperative tumor volumes were assessed and compared to those of the conventional staging system based on tumor diameter in patients with T1N0 PTC.

Materials and Methods
=====================

1. Patients, follow-up, and measurements
----------------------------------------

This study's retrospective design was approved by the Institutional Review Board of St. Vincent's Hospital. We retrospectively reviewed data from 2,585 patients who were diagnosed with thyroid cancer and treated at St. Vincent's Hospital between February 1982 and December 2012. All patients were treated by total thyroidectomy or lobectomy with isthmectomy, and central lymph node dissection was performed when lymph node metastasis was suspected during the preoperative evaluation. The postoperative pathological reports confirmed that all patients had tumor-free margins. Thyroid-stimulating hormone suppression therapy was administered during the follow-up period, and nonstimulated serum thyroglobulin measurements and neck ultrasonography (with or without neck and chest computed tomography) were routinely performed every 6-12 months.

Among the eligible patients, we identified 1,659 patients with T1N0 PTC. However, to create a homogenous study population, we excluded patients with aggressive histological variants (solid, insular, columnar, tall cell, or diffuse sclerosing), lymphovascular invasion, multifocal malignancies, extrathyroidal extension, or capsular invasion, as well as those who had received postoperative radioactive iodine therapy. We also excluded patients who had a cystic tumor portion or poorly defined margins to ensure that the tumor volume could be accurately calculated. Thus, 1,081 patients were selected for inclusion in this study.

All 1,081 patients had undergone preoperative ultrasonography to examine the thyroid tumor. Three experienced radiologists, each with more than 5 years of thyroid ultrasound experience, had evaluated the tumor's dimensions (using transverse and sagittal orthogonal scans) and cervical lymph node status. The recorded dimensions were transverse length (T), longitudinal length (L), and depth (D), which allowed us to calculate the tumor's volume (V) using the ellipsoid formula (V=T \[cm\]×L \[cm\]×D \[cm\]×π/6).

2. Statistical analysis
-----------------------

The clinicopathological variables that we evaluated included age at diagnosis, sex, surgery type, histological subtype, and tumor location. All patients were categorized according to tumor diameter as T1a (≤ 1 cm) or T1b (\> 1 cm but ≤ 2 cm). We next performed receiver operating characteristic (ROC) curve analysis to estimate the optimal cut-off tumor volume for predicting recurrence. Based on the result of the ROC analysis, we also categorized the patients according to tumor volume as V1a or V1b. To validate the results of the ROC analysis, an internal validation was performed using the 1,000 bootstrap resampling method.

The primary outcome of interest in the study was recurrence-free survival (RFS). RFS was defined as the period between the date of the initial surgery and the first instance of contralateral lobe, locoregional (the operative bed, trachea, strap muscle, or cervical lymph nodes), or distant recurrence or the last follow-up. The presence of a contralateral lobe or locoregional recurrence was based on cytological or histopathological evidence of disease in specimens obtained by fine-needle aspiration biopsy or surgical excision. We did not use serum thyroglobulin levels to identify recurrent disease, as they do not definitively diagnose recurrent or persistent disease in patients who have not undergone total thyroidectomy.

Independent t tests and chi-square tests were used to evaluate inter-group differences in the clinicopathological variables. Survival curves were created using the Kaplan-Meier method and compared using the log-rank test. Multivariate analyses were performed using Cox's proportional hazard regression model to assess the independent prognostic values of tumor volume and tumor diameter, and hazard ratios and 95% confidence intervals (CIs) were estimated for each variable. Because age is a known prognostic factor in PTC, we also conducted subgroup analyses using a cut-off age of 45 years. All statistical tests were two-sided, and p-values of \< 0.05 were considered to indicate significance. All statistical analyses were performed using the SPSS ver. 12.0 (SPSS Inc., Chicago, IL).

Results
=======

1. Cut-off tumor volume for predicting recurrence
-------------------------------------------------

The ROC curve analysis ([Fig. 1](#f1-crt-2016-325){ref-type="fig"}) revealed that the optimal cut-off volume for predicting tumor recurrence was 0.545 cm^3^, which provided an area under the curve of 0.712 (95% CI, 0.610 to 0.814; p \< 0.001; sensitivity 50.0%; specificity 85.3%). Therefore, patients were categorized as having a tumor volume of V1a (≤ 0.545 cm^3^) or V1b (\> 0.545 cm^3^). The cutoff value obtained from the ROC analysis was internally validated using the bootstrap method. The estimated concordance probability determined by 1,000 repetitions of the bootstrap sample corrections was 0.713 (95% CI, 0.602 to 0.806).

2. Comparison of patient and tumor characteristics among tumor groups
---------------------------------------------------------------------

The baseline characteristics of the study cohorts are shown in [Table 1](#t1-crt-2016-325){ref-type="table"}. The mean age of the entire cohort was 48.14±10.74 years. Eighty-nine patients were moved from the T1b group to the V1a group (26 were aged \< 45 years, and 63 were aged ≥ 45 years). Total thyroidectomy was more performed more often in the T1b group than in the T1a group (55.4% vs. 28.3%, respectively; p \< 0.001). Moreover, comparison of groups V1b and V1a revealed significant differences in the number of right lobe tumors (55.0% vs. 53.2%, respectively; p=0.005), isthmus tumors (7.1% vs. 2.5%, respectively; p=0.005), and total thyroidectomies (58.6% vs. 30.4%, respectively; p \< 0.001).

Age-based subgroup analyses ([Table 2](#t2-crt-2016-325){ref-type="table"}) showed that total thyroidectomy was significantly more frequent in \< 45-yearold patients in group T1b than group T1a (44.8% vs. 20.6%, respectively; p \< 0.001) and group V1b than group V1a (45.7% vs. 22.2%, respectively; p \< 0.001). There were also significantly more histological variants in younger patients in group T1b than group T1a (9.4% vs. 3.4%, respectively; p=0.015). When we compared the ≥ 45-year-old patients in groups T1b and T1a, we found significant differences in the number of right lobe tumors (56.8% vs. 53.0%, respectively; p=0.043), isthmus tumors (5.6% vs. 2.2%, respectively; p=0.043), and total thyroidectomies (61.7% vs. 33.3%, respectively; p \< 0.001). When we compared the ≥ 45-year-old patients in groups V1b and V1a, we found similar differences in the number of right lobe tumors (58.6% vs. 53.1%, respectively; p=0.002), isthmus tumors (8.1% vs. 2.1%, respectively; p=0.002), and total thyroidectomies (67.7% vs. 35.5%, respectively; p \< 0.001).

3. Tumor recurrence patterns
----------------------------

The mean follow-up time was 66.12±28.75 months, and 97.2% of the entire cohort experienced RFS. [Table 3](#t3-crt-2016-325){ref-type="table"} provides detailed information regarding tumor recurrence in the study population. Thirty patients experienced tumor recurrence, with 17 cases of contralateral lobe recurrence and 12 cases of locoregional recurrence. Only one patient experienced distant recurrence (lung metastasis), which was detected via chest computed tomography and confirmed by excisional biopsy. None of the patients who were moved from the T1b group to the V1a group experienced tumor recurrence.

4. Analysis of the rates of RFS
-------------------------------

There was no significant difference in RFS rates between the T1a and T1b groups (98.2% vs. 94.2%, respectively; p=0.997) or the V1a and V1b groups (98.4% vs. 91.1%, respectively; p=0.253) ([Fig. 2A](#f2-crt-2016-325){ref-type="fig"}). Multivariate analysis provided similar findings ([Table 4](#t4-crt-2016-325){ref-type="table"}).

When we conducted subgroup analyses using a cut-off age of 45 years, no significant differences in RFS rates were observed between the \< 45-year-old patients in either the T1a/T1b groups (98.2% vs. 95.8%, respectively; p=0.137) or the V1a/V1b groups (98.3% vs. 94.4%, respectively; p=0.236) ([Fig. 2B](#f2-crt-2016-325){ref-type="fig"} and [C](#f2-crt-2016-325){ref-type="fig"}). However, ≥ 45-year-old patients in the V1b group showed significantly poorer RFS rates than those in the V1a group (88.9% vs. 98.4%, respectively; p=0.029) ([Fig. 2C](#f2-crt-2016-325){ref-type="fig"}). Multivariate analyses revealed no significant agerelated differences in RFS rates between the T1a and T1b groups. However, poorer RFS rates were associated with older patients in group V1b than V1a upon multivariate analysis (hazard ratio, 2.676; 95% CI, 1.075 to 6.661; p=0.034) ([Table 4](#t4-crt-2016-325){ref-type="table"}).

Discussion
==========

The present study assessed the prognostic value of preoperative tumor volume and compared it to that of the conventional staging system based on tumor diameter in patients with T1N0 PTC. We found that tumor volume better predicted tumor recurrence than the conventional staging system in ≥ 45-year-old patients with T1N0 PTC. Accurately measuring the tumor's diameter may be hindered by the fact that tumors exhibit various shapes; hence, tumor volume may more precisely reflect tumor burden. Several studies have evaluated the prognostic value of tumor volume and tumor diameter in non-thyroid cancers, including non-small cell lung cancer and oropharyngeal cancer \[[@b11-crt-2016-325],[@b12-crt-2016-325]\]. Furthermore, Park et al. \[[@b13-crt-2016-325]\] reported an association between tumor volume and occult central lymph node metastasis in PTC. However, to the best of our knowledge, this is the first study to compare the prognostic value of preoperative tumor diameter and tumor volume in early-stage node-negative papillary cancer.

There is debate regarding whether patients with T1a papillary cancer have a different prognosis than those with T1b papillary cancer \[[@b14-crt-2016-325]-[@b16-crt-2016-325]\]. Although the current AJCC staging system subdivides T1 disease into T1a and T1b based on a tumor diameter of 1 cm, this subdivision does not affect the final tumor stage as the seventh version of the AJCC staging system defines both T1a and T1b disease as stage 1 for nodenegative patients who are aged ≥ 45 years. This raises the question of whether it is necessary to subdivide T1 disease into T1a and T1b. However, we found a difference in prognosis when we compared ≥ 45-year-old patients in the V1a and V1b groups. Therefore, it may be useful to consider subdividing stage 1 PTC according to tumor volume, especially in patients aged ≥ 45 years, to more precisely predict their prognosis.

In the present study, 89 patients were reclassified from T1b to V1a based on their tumor volume, and none of these patients experienced tumor recurrence. These findings highlight the possibility of misclassification in the current staging system, which is based on tumor diameter. Our results suggest that use of tumor volume for staging might reduce the possibility of misclassification. In addition, it may be appropriate to include tumor volume as a criterion for active surveillance of low-risk PTC in the 2015 revision of the American Thyroid Association guidelines, which currently only consider tumor diameter.

It should be noted that this study has several limitations. First, its single-center retrospective design has well-known risks of bias. Second, discordance between tumor volumes measured via preoperative ultrasonography versus pathology is possible, as is interobserver variation during the approximately 30-year data collection period. However, several studies have reported that preoperative ultrasonography reliably estimates the size of thyroid cancers and has low interobserver variability \[[@b17-crt-2016-325],[@b18-crt-2016-325]\]. Third, the relatively short follow-up period and limited number of recurrences might limit the statistical power of our analysis. Therefore, larger studies with prolonged follow-ups should be conducted to validate our findings. Finally, we did not consider genetic data (e.g., *BRAF* mutation status), which can be useful for predicting prognosis in patients with PTC.

Our findings show that preoperative tumor volume better predicts prognosis than the conventional staging system based on tumor diameter in ≥ 45-year-old patients with T1N0 PTC. Therefore, we suggest that future risk stratification systems should consider tumor volume as a prognostic factor for such patients.
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###### 

Baseline patient characteristics

  Characteristic             Tumor diameter   Tumor volume                                          
  -------------------------- ---------------- -------------- ---------- ------------- ------------- ----------
  **Tumor size (cm)**                                                                               
   Mean±SD                   0.64±0.19        1.38±0.27                 0.69±0.24     1.50±0.25     
  **Sex**                                                                                           
   Female                    734 (89.2)       222 (86.0)     0.169      808 (88.6)    148 (87.6)    0.703
   Male                      89 (10.8)        36 (14.0)                 104 (11.4)    21 (12.4)     
  **Age (yr)**                                                                                      
   Mean±SD                   48.00±10.50      48.58±11.47               48.14±10.49   48.15±12.03   
   \< 45                     325 (39.5)       96 (37.2)      0.512      351 (38.5)    70 (41.4)     0.473
   ≥ 45                      498 (60.5)       162 (62.8)                561 (61.5)    99 (58.6)     
  **Surgery**                                                                                       
   Lobectomy+isthmectomy     590 (71.7)       115 (44.6)     \< 0.001   635 (69.6)    70 (41.4)     \< 0.001
   Total thyroidectomy       233 (28.3)       143 (55.4)                277 (30.4)    99 (58.6)     
  **Histological subtype**                                                                          
   Classic                   776 (94.3)       238 (92.2)     0.235      857 (94.0)    157 (92.9)    0.596
   Follicular variant        47 (5.7)         20 (7.8)                  55 (6.0)      12 (7.1)      
  **Location**                                                                                      
   Right                     439 (53.3)       139 (53.9)     0.062      485 (53.2)    93 (55.0)     0.005
   Left                      363 (44.1)       105 (40.7)                404 (44.3)    64 (37.9)     
   Isthmus                   21 (2.6)         14 (5.4)                  23 (2.5)      12 (7.1)      
  **CLND**                                                                                          
   Performed                 466 (56.6)       147 (57.0)     0.920      514 (56.4)    99 (58.6)     0.593
   Not performed             357 (43.4)       111 (43.0)                398 (43.6)    70 (41.4)     

Values are presented as number (%) unless otherwise indicated. SD, standard deviation; CLND, central lymph node dissection.

###### 

Baseline patient characteristics using a cut-off age of 45 years

  Variable                   Age \< 45 yr   Age ≥ 45 yr                                                                                                                
  -------------------------- -------------- ------------- ---------- ------------ ----------- ---------- ------------ ------------ ---------- ------------ ----------- ----------
  **Tumor size (cm)**                                                                                                                                                  
   Mean±SD                   0.63±0.19      1.38±0.27                0.67±0.22    1.47±0.25              0.64±0.20    1.38±0.27               0.70±0.25    1.51±0.26   
  **Sex**                                                                                                                                                              
   Female                    284 (87.4)     81 (84.4)     0.446      306 (87.2)   59 (84.3)   0.515      450 (90.4)   141 (87.0)   0.230      502 (89.5)   89 (89.9)   0.901
   Male                      41 (12.6)      15 (15.6)                45 (12.8)    11 (15.7)              48 (9.6)     21 (13.0)               59 (10.5)    10 (10.1)   
  **Surgery**                                                                                                                                                          
   Lobectomy+isthmectomy     258 (79.4)     53 (55.2)     \< 0.001   273 (77.8)   38 (54.3)   \< 0.001   332 (66.7)   62 (38.3)    \< 0.001   362 (64.5)   32 (32.3)   \< 0.001
   Total thyroidectomy       67 (20.6)      43 (44.8)                78 (22.2)    32 (45.7)              166 (33.3)   100 (61.7)              199 (35.5)   67 (67.7)   
  **Histological subtype**                                                                                                                                             
   Classic                   314 (96.6)     87 (90.6)     0.015      337 (96.0)   64 (91.4)   0.120      462 (92.8)   151 (93.2)   0.850      520 (92.7)   93 (93.9)   0.656
   Follicular variant        11 (3.4)       9 (9.4)                  14 (4.0)     6 (8.6)                36 (7.2)     11 (6.8)                41 (7.3)     6 (6.1)     
  **Location**                                                                                                                                                         
   Right                     175 (53.8)     47 (49.0)     0.494      187 (53.3)   35 (50.0)   0.544      264 (53.0)   92 (56.8)    0.043      298 (53.1)   58 (58.6)   0.002
   Left                      140 (43.1)     44 (45.8)                153 (43.6)   31 (44.3)              223 (44.8)   61 (37.7)               251 (44.7)   33 (33.3)   
   Isthmus                   10 (3.1)       5 (5.2)                  11 (3.1)     4 (5.7)                11 (2.2)     9 (5.6)                 12 (2.1)     8 (8.1)     
  **CLND**                                                                                                                                                             
   Performed                 190 (58.5)     54 (56.3)     0.700      201 (57.3)   43 (61.4)   0.519      276 (55.4)   93 (57.4)    0.658      313 (55.8)   56 (56.6)   0.887
   Not performed             135 (41.5)     42 (43.8)                150 (42.7)   27 (38.6)              222 (44.6)   69 (42.6)               248 (44.2)   43 (43.4)   

Values are presented as number (%) unless otherwise indicated. SD, standard deviation; CLND, central lymph node dissection.

###### 

Tumor recurrence patterns in the study population

  Variable               Age \< 45 yr   Age ≥ 45 yr                                                                   
  ---------------------- -------------- ------------- ------------ ----------- ------------ ------------ ------------ -----------
  **Tumor recurrence**                                                                                                
   No                    319 (98.2)     92 (95.8)     345 (98.3)   66 (94.3)   489 (98.2)   151 (93.2)   552 (98.4)   88 (88.9)
   Yes                   6 (1.8)        4 (4.2)       6 (1.7)      4 (5.7)     9 (1.8)      11 (6.8)     9 (1.6)      11 (11.1)
  **Recurrence site**                                                                                                 
   Contralateral lobe    4 (66.7)       3 (75.0)      4 (66.7)     3 (75.0)    6 (66.7)     4 (36.4)     6 (66.7)     4 (36.4)
   Locoregional          2 (33.3)       1 (25.0)      2 (33.3)     1 (25.0)    2 (22.2)     7 (63.6)     2 (22.2)     7 (63.6)
   Distant               0              0             0            0           1 (11.1)     0            1 (11.1)     0

Values are presented as number (%).

###### 

Multivariate analysis of tumor recurrence

  Variable             Total                                                                Age \< 45 yr   Age ≥ 45 yr                                                                                                                                       
  -------------------- -------------------------------------------------------------------- -------------- -------------------------------------------------------------------- ------- -------------------------------------------------------------------- -------
  **Tumor diameter**                                                                                                                                                                                                                                         
   T1a                 1                                                                                   1                                                                            1                                                                    
   T1b                 1.071 (0.471-2.439)^[a)](#tfn1-crt-2016-325){ref-type="table-fn"}^   0.869          0.240 (0.026-2.205)^[b)](#tfn2-crt-2016-325){ref-type="table-fn"}^   0.207   1.685 (0.652-4.352)^[c)](#tfn3-crt-2016-325){ref-type="table-fn"}^   0.281
  **Tumor volume**                                                                                                                                                                                                                                           
   V1a                 1                                                                                   1                                                                            1                                                                    
   V1b                 1.701 (0.754-3.836)^[c)](#tfn3-crt-2016-325){ref-type="table-fn"}^   0.200          0.284 (0.031-2.619)^[a)](#tfn1-crt-2016-325){ref-type="table-fn"}^   0.267   2.676 (1.075-6.661)^[c)](#tfn3-crt-2016-325){ref-type="table-fn"}^   0.034

HR, hazard ratio; CI, confidence interval.

Adjusted for surgery,

Adjusted for surgery, histologic subtype,

Adjusted for surgery, tumor location.
